Comparative effectiveness in thyroid cancer: key questions and how to answer them. Cancer Treat Res 2015;164:67-87
Date
02/14/2015Pubmed ID
25677019DOI
10.1007/978-3-319-12553-4_5Scopus ID
2-s2.0-84923347205 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Controversies in treatment of thyroid cancer remain despite numerous published studies. Robust comparative effectiveness studies examining: (1) the role of prophylactic central compartment neck dissection (pCCND) in patients with papillary thyroid cancer (PTC); (2) the use of post-operative radioactive iodine (RAI) ablation therapy following total thyroidectomy; (3) use of low versus high doses of I-131 in RAI therapy; (4) thyroid hormone withdrawal (THW) versus recombinant thyroid stimulating hormone (rhTSH) prior to RAI; and (5) the role of routine measurement of serum calcitonin levels are needed to help strengthen existing treatment recommendations. Reasons for the controversies and suggestions for quality comparative effectiveness studies are discussed.
Author List
Asare EA, Wang TSAuthor
Tracy S. Wang MD, MPH Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
CalcitoninCarcinoma
Carcinoma, Papillary
Comparative Effectiveness Research
Humans
Iodine Radioisotopes
Neck Dissection
Neoplasm Recurrence, Local
Radiotherapy
Recombinant Proteins
Thyroid Neoplasms
Thyrotropin
Treatment Outcome